The interactions of these risk factors with possible radiation effects are unknown, but confounding or effect modification cannot be ruled out in studies in which no adjustment was made; in the two cohorts where it was possible to make adjustment for such risk factors little difference was made to radiation risk (Azizova et al. 2010a, 2010b; Shimizu et al. 2010).
In addition, increased tissue damage due to sharpness following deformation or shape modification cannot be ruled out.
Although the possibility of not recovering all minor isoforms and rare modifications cannot be ruled out in our analysis, the MS data already suggests that the AT1R activation/inhibition causes fluctuation of several interesting and perhaps unique isoforms (i.e., Q96QV6, H2Q, H2AAme1, H2AQAc and H2AL) and PTM (Table 2), which must alter the composition of the nucleosome.
Therefore, a possibility of phosphorylation as a requisite for O-GlcNAc modification may not be ruled out.
No such variation is found in mammalian mt-rRNA, at least at the nucleotide sequence level, where the vast majority are identical, although variation in modification status cannot be ruled out.
In addition, some other properties (influence of substrate and reaction conditions on the lid movement, differences in the glycosylation degree, post-translational modifications) should not be ruled out.
Nevertheless, the possibility that NvHsTRPA undergoes the other post-translational modifications can not be ruled out.
The levels of both modifications were higher in ovarian cancer patients than in healthy controls although in the case of the formamide modification age could not be ruled out as a factor.
Until such variables can be ruled out, putting the blame on genetic modification is premature.
Therefore inspection or modification of data or software by the Cloud provider cannot be ruled out.
